Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
| Autor: | Barry N. Lutsky, R Suárez-Chacón, U Harnest, Jacques Hébert, Jean Bousquet, Bo Lundbäck, G Martinez Morales, S Visser, M M Nieminen, C H Barraza, Anthony D'Urzo, K.B. Nolop, L.-P. Boulet |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Pulmonary and Respiratory Medicine
Budesonide Adult Male Time Factors Adolescent medicine.drug_class Anti-Inflammatory Agents Mometasone furoate law.invention Randomized controlled trial law Forced Expiratory Volume medicine Humans Albuterol Single-Blind Method Lung Pregnadienediols Asthma Aged Inhalation business.industry Nebulizers and Vaporizers Middle Aged medicine.disease Total Daily Dose Dry-powder inhaler Bronchodilator Agents Circadian Rhythm Anesthesia Corticosteroid Drug Therapy Combination Female Powders Safety business Sleep Mometasone Furoate medicine.drug |
| Zdroj: | The European respiratory journal. 16(5) |
| ISSN: | 0903-1936 |
| Popis: | Mometasone furoate (MF) administered by dry powder inhaler (DPI) was composed with budesonide (BUD) Turbuhaler in the treatment of moderate persistent asthma. The patients were randomized to one of four treatment groups: MF DPI (100, 200, 400 microg b.i.d) or BUD Turbuhaler. 400 microg b.i.d in a 12-week, active-controlled, evaluator-blind, multicentre international trial. The primary efficacy variable was the mean change from baseline to endpoint (last treatment visit) in forced expiratory volume in one second (FEV1). Changes in FEV1 showed a statistically significant superiority (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|